Sugi Predict

Sugi Predict / Compounds / SCHEMBL531767

SCHEMBL531767

SCHEMBL531767

Nc1nnc(Cl)cc1-c1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMARCA2 P51531 3/20 0.66
▸ PBRM1 Q86U86 3/20 0.66
▸ SMARCA4 P51532 2/20 0.66
▸ BRD4 O60885 1/20 0.54
▸ NR1I2 O75469 1/20 0.54
▸ MAP4K4 O95819 2/20 0.49
▸ CYP2A6 P11509 1/20 0.45
▸ FGFR1 P11362 1/20 0.45
▸ SRC P12931 1/20 0.45
▸ KDM4E B2RXH2 2/20 0.43
▸ HSP90AA1 P07900 1/20 0.43
▸ HSP90AB1 P08238 1/20 0.43
▸ USP7 Q93009 2/20 0.41
▸ ALDH1A1 P00352 3/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ ADORA2A P29274 3/20 0.40
▸ ADORA1 P30542 3/20 0.40
▸ LMNA P02545 1/20 0.39
▸ GLA P06280 1/20 0.39
▸ HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenylboronic Acid SCHEMBL18038666 0.87 SMARCA2 (0.51) SMARCA2PBRM1SMARCA4BRD4NR1I2
SCHEMBL25348245 0.84 SMARCA2 (0.46) SMARCA2PBRM1SMARCA4BRD4NR1I2
SCHEMBL31218502 0.81 USP7 (0.58) SMARCA2PBRM1SMARCA4BRD4NR1I2
SCHEMBL25346565 0.81 USP7 (0.58) SMARCA2PBRM1SMARCA4BRD4NR1I2
SCHEMBL29414855 0.80 DHFR (0.51) SMARCA2PBRM1SMARCA4CYP2A6SRC
SCHEMBL22632800 0.80 DHFR (0.51) SMARCA2PBRM1SMARCA4CYP2A6SRC
SCHEMBL21994858 0.80 KDM4E (0.45) SMARCA2PBRM1SMARCA4BRD4NR1I2
SCHEMBL527009 0.79 CYP2A6 (0.43) SMARCA2PBRM1SMARCA4CYP2A6KDM4E
SCHEMBL30041839 0.79 CYP2A6 (0.43) SMARCA2PBRM1SMARCA4CYP2A6KDM4E
SCHEMBL29912639 0.79 SMARCA2 (1.00) SMARCA2PBRM1SMARCA4BRD4NR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3262036-B1 THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF GENENTECH INC (US) 2023-09-13 — — EP disclosed
EP-3262036-B1 THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF GENENTECH INC (US) 2023-09-13 — — EP disclosed
US-20230002367-A1 BIFUNCTIONAL COMPOUNDS C4 THERAPEUTICS, INC. 2023-01-05 — — US disclosed
CN-107531668-B Therapeutic pyridazine compounds and uses thereof 基因泰克公司 2021-10-29 — — CN disclosed
US-10308614-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2019-06-04 — — US disclosed
US-10308614-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2019-06-04 — — US disclosed
US-20180086720-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2018-03-29 — — US disclosed
US-20180086720-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2018-03-29 — — US disclosed
US-20180086720-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2018-03-29 — — US disclosed
EP-3262036-A1 THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF Genentech, Inc. (US) 2018-01-03 — — EP disclosed
EP-2834226-B1 1,2-PYRIDAZINE, 1,6-PYRIDAZINE OR PYRIMIDINE-BENZAMIDE DERIVATIVES AS GPBAR1 MODULATORS HOFFMANN LA ROCHE (CH) 2016-05-25 — — EP disclosed
US-8987273-B2 Substituted imidazo[1,2-B]pyridazines BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-03-24 — — US disclosed
EP-2598505-B1 SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES BAYER IP GMBH (DE) 2015-03-18 — — EP disclosed
EP-2834226-A1 1,2- PYRIDAZINE, 1,6- PYRIDAZINE OR PYRIMIDINE - BENZAMIDE DERIVATIVES AS GPBAR1 MODULATORS F. Hoffmann-La Roche AG (CH) 2015-02-11 — — EP disclosed
US-8748434-B2 1,2-pyridazines, 1,6-pyridazines and pyrimidines ROCHE PALO ALTO LLC (US) 2014-06-10 — — US disclosed
US-20130267519-A1 1,2-PYRIDAZINES, 1,6-PYRIDAZINES AND PYRIMIDINES HOFFMANN-LA ROCHE INC. (US) 2013-10-10 — — US disclosed
WO-2013149977-A1 1,2- PYRIDAZINE, 1,6- PYRIDAZINE OR PYRIMIDINE - BENZAMIDE DERIVATIVES AS GPBAR1 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2013-10-10 — — WO disclosed
US-20130210825-A1 SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-08-15 — — US disclosed
EP-2598505-A2 SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES Bayer Intellectual Property GmbH (DE) 2013-06-05 — — EP disclosed
WO-2012013713-A2 SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-02-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10308614-B2 Therapeutic compounds and uses thereof SMARCC1, SMARCC2, SMARCA4 SMARCA2 10/4885PBRM1 11/4885SMARCA4 3/4885
US-20180086720-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF SMARCC1, SMARCC2, SMARCA4 SMARCA2 10/4885PBRM1 11/4885SMARCA4 3/4885
US-20130267519-A1 1,2-PYRIDAZINES, 1,6-PYRIDAZINES AND PYRIMIDINES GPBAR1, P2RY1, P2RY2 SMARCA2 4712/4885PBRM1 1160/4885SMARCA4 4645/4885
US-20130210825-A1 SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES NRAS, IDH2, NDUFB1 SMARCA2 430/4885PBRM1 51/4885SMARCA4 492/4885
US-20230002367-A1 BIFUNCTIONAL COMPOUNDS ITCH, EGFR, MUC1 SMARCA2 3260/4885PBRM1 1119/4885SMARCA4 3599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.